PYNNACLE trial
Rezatapopt Shows Early Promise in TP53 Y220C-Mutant Tumors in PYNNACLE Phase II Trial
Rezatapopt; TP53 Y220C mutation; PYNNACLE trial; solid tumors; phase II clinical trial; ORR; ovarian cancer; p53 reactivator; targeted therapy; PMV Pharmaceuticals